Academic Publications From The SeroTracker Team

From most recent to least recent (1-21)

1. Toews, E., Shaikh, S., Akter, S., Zhang, C., Selemon, A., Arora, R.K., Bobrovitz, N., Jaenisch, T., Ware, H. and Whelan, M.G., 2025.

   Serological and viral prevalence of Oropouche virus (OROV): A systematic review and meta-analysis from 2000-2024 including human, animal, and vector surveillance studies

   . medRxiv, pp.2025-07

2. Cao C, Arora R, Cento P, Manta K, Farahani E, Cecere M, Selemon A, Sang J, Gong LX, Kloosterman R, Jiang S.

   Automation of Systematic Reviews with Large Language Models

   . medRxiv. 2025 Jun 13:2025-06.

3. Cao C, Sang J, Arora R, Chen D, Kloosterman R, Cecere M, et al.

   Development of Prompt Templates for Large Language Model–Driven Screening in Systematic Reviews

   . Ann Intern Med. 2025 Mar;178(3):389–401.

4. Whelan MG, Ware H, Ranka H, Kenny S, Shaikh S, Roell Y, et al.

   ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies

   . Lancet Infect Dis. 2024 Nov;24(11):e670–1.

5. Cheng B, Loeschnik E, Selemon A, Hosseini R, Yuan J, Ware H, et al.

   Adherence of SARS‐CoV‐2 Seroepidemiologic Studies to the ROSES‐S Reporting Guideline During the COVID‐19 Pandemic

   . Influenza Other Respir Viruses. 2024 Jul;18(7):e13283.

6. Müller SA, Agweyu A, Akanbi OA, Alex-Wele MA, Alinon KN, Arora RK, et al.

   Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response

   . The Lancet. 2023 Jul;402(10399):356–8.

7. Farley E, Okeibunor J, Balde T, Donkor IO, Kleynhans J, Wamala JF, et al.

   Short communication—Lessons learnt during the implementation of Unity‐aligned SARS‐CoV‐2 seroprevalence studies in Africa

   . Influenza Other Respir Viruses. 2023 Aug;17(8):e13170.

8. Perlman‐Arrow S, Loo N, Bobrovitz N, Yan T, Arora RK.

   A real‐world evaluation of the implementation of NLP technology in abstract screening of a systematic review

   . Res Synth Methods. 2023 Jul;14(4):608–21.

9. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al.

   Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression

   . Lancet Infect Dis. 2023 May;23(5):556–67.

10. Bobrovitz N, Noël K, Li Z, Cao C, Deveaux G, Selemon A, et al.

    SeroTracker-RoB: an approach to automating reproducible risk of bias assessment of seroprevalence studies

    [Internet]. medRxiv; 2022 [cited 2022 Jun 4]. p. 2021.11.17.21266471.

11. Boucher E, Cao C, D’Mello S, Duarte N, Donnici C, Duarte N, et al.

    Occupation and SARS-CoV-2 seroprevalence studies: a systematic review

    . BMJ Open. 2023 Feb;13(2):e063771.

12. Cable J, Fauci A, Dowling WE, Günther S, Bente DA, Yadav PD, et al.

    Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report

    . Ann N Y Acad Sci. 2022 Dec;1518(1):209–25.

13. Donnici C, Ilincic N, Cao C, Zhang C, Deveaux G, Clifton DA, et al.

    Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance

    [Internet]. medRxiv; 2022 [cited 2022 Apr 27]. p. 2022.02.17.22271099.

14. Ma X, Li Z, Whelan MG, Kim D, Cao C, Yanes-Lane M, et al.

    Serology Assays Used in SARS-CoV-2 Seroprevalence Surveys Worldwide: A Systematic Review and Meta-Analysis of Assay Features, Testing Algorithms, and Performance

    . Vaccines. 2022 Nov 24;10(12):2000.

15. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al.

    SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021

    . BMJ Glob Health. 2022 Aug;7(8):e008793.

16. Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al.

    Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies

    . Suthar AB, editor. PLOS Med. 2022 Nov 10;19(11):e1004107.

17. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, et al.

    Adapting Serosurveys for the SARS-CoV-2 Vaccine Era

    . Open Forum Infect Dis. 2022 Feb 1;9(2):ofab632.

18. Van Kerkhove M, Grant R, Subissi L, Valenciano M, Glonti K, Bergeri I, et al.

    ROSES-S: Statement from the World Health Organization on the reporting of Seroepidemiologic studies for SARS-CoV-2

    . Influenza Other Respir Viruses. 2021 May;In press.

19. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Rahim H, et al.

    Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis

    . PLoS ONE [Internet]. 2021 Jun 23 [cited 2021 Mar 7];16(6).

20. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al.

    SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

    . Lancet Infect Dis [Internet]. [cited 2020 Nov 11];

21. Bobrovitz N, Arora RK, Yan T, Rahim H, Duarte N, Boucher E, et al.

    Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys

    . medRxiv. 2020 May 14;2020.05.10.20097451.